The Medical Journal of Australia ISSN: 0025-729X 17 June 2013 198 11 628-624 ©The Medical Journal of Australia 2013 www.mja.com.au Research ertussis, commonly known as whooping cough, is caused by the small, gram-negative coccobacillus Bordetella pertussis. Classic whooping cough illness is characterised by intense paroxysmal coughing followed by an inspiratory "whoop", especially in young children or those without prior immunity, followed by a protracted cough. 1, 2 It is now more widely understood that these characteristic symptoms are not always present during B. pertussis infection, and that individuals may only have symptoms similar to those of the common cold or a non-specific upper respiratory tract infection. 2 In recent years, rates of pertussis notifications have increased dramatically across Australia and in many other parts of the world. [3] [4] [5] [6] The rise has been seen in all Australian states and territories, with the highest notification rates in children aged under 15 years. 7 Although increased notifications may be due to a true increase in circulating B. pertussis, it is possible that the magnitude of the increase has been amplified by better recognition of disease and more frequent testing. 8 Historically, the diagnostic gold standard for pertussis laboratory testing was bacterial culture from nasopharyngeal secretions during the early phases of infection (Weeks 1 and 2), and serological testing was used as an alternative diagnostic method during later phases of infection. 2 However, even with ideal specimen collection, transport and handling, culture has low sensitivity and does not provide timely results. Although serological testing is more sensitive, sensitivity and specificity may be lowered depending on the timing of specimen collection and the patient's infection and vaccination history. Polymerase chain reaction (PCR) testing has emerged as a key diagnostic method, and respiratory specimens are now commonly tested for pertussis using PCR in Australia and other countries.
2,4,10 PCR testing provides more sensitive and rapid results than culture and serological testing. Also, PCR allows less invasive specimen collection -especially useful in younger age groups, in whom infection rates are high and serum collection may be challenging. 1 The key datasets used to monitor pertussis incidence and epidemiology in Australia -pertussis notifications, and pertussis-coded hospitalisations and deaths -are populated by positive test results from laboratories and, as such, are not independent of changes in testing practices. Without negative test results or other denominator data to assess changes in testing behaviour, it is difficult to distinguish changes in recorded disease incidence that are due to the effect of increased testing from any true increase in disease.
To better understand the role testing behaviour has on current pertussis epidemiology in Australia, we investigated pertussis testing trends in a stable set of general practice encounters. We hypothesised that the likelihood of pertussis testing, in a stable set of encounters that were most likely to result in a pertussis test request, has increased over time and that this may have led to amplification of laboratory-confirmed pertussis identification in Australia.
Methods
We analysed data from the Bettering the Evaluation and Care of Health (BEACH) program and the National Notifiable Diseases Surveillance System (NNDSS).
The BEACH program is a continuous cross-sectional national study that began collecting details of Australian general practice encounters in April 1998. Study methods for the BEACH program have been described elsewhere 11 and are summarised in Appendix 1 (online at mja.com.au). Conclusion: An increase in pertussis testing following recognition of early epidemic cases may have led to identification of previously undetected infections, resulting in a further increase in notified disease and awareness among GPs. The changing likelihood of being tested may also be due to expanding availability and use of PCR testing in Australia. The NNDSS collates notifications of confirmed and probable pertussis cases received in each state and territory of Australia under appropriate public health legislation. 13 Notified cases meet a pertussis case definition, which requires: laboratory definitive evidence; or laboratory suggestive evidence and clinical evidence; or clinical evidence and epidemiological evidence (Appendix 3; online at mja.com.au).
To match the BEACH years, all Australian pertussis notifications between April 2000 and March 2011 were extracted from the NNDSS database, including data on age and laboratory testing method. Pertussis notifications were aggregated by month and year, by age group, and by laboratory test method (serological, PCR, culture or unknown). Notifications that had more than one testing modality reported were classified into a single test category using the following hierarchy: culture, PCR, serological, unknown. A total of 1318 notifications were coded only as "antigen detection", "histopathology", "microscopy", "not done" or "other" (epidemiologically linked cases); these were excluded from the analysis as they accounted for only 0.9% of notifications over the study period. The rates of pertussis notifications per 100 000 population were then calculated for each pre-epidemic period and epidemic year.
Temporal changes in the proportions of PRPs with a pertussis test ordered and the rates of pertussis notifications were assessed with a non-parametric test for trend over the whole study period and by calculating odds ratios with robust 95% confidence intervals. Correlation coefficients were calculated to determine the relationship between BEACH and NNDSS datasets. The BEACH analyses incorporated an adjustment for the cluster sample design. Initial BEACH analyses were performed using SAS version 9. When the BEACH data were grouped into pre-epidemic periods and epidemic years, the proportion of PRPs with a pertussis test ordered increased about sevenfold -from 0.25% to 1.71% -when comparing In the age-specific analysis, there were significant increases in laboratory-confirmed pertussis notifications and in the likelihood of pertussis test requests across all age groups during the study period (Box 3). When comparing April 2000 -March 2004 and April 2010 -March 2011 pertussis testing rates, the largest increase was in 5-9-year-olds (odds ratio, 11.6; 95% CI, 4.2-36.7), followed by 0-4-year-olds, 40-59-year-olds and у 60-year-olds. With the exception of 5-9-year-olds, the increase in pertussis 4, 7, 10, 13 The increased likelihood of testing in general practice coincided with an increasing proportion of NNDSS pertussis notifications being confirmed Pertussis notification rates and the likelihood of testing varied considerably across age groups. There was a dramatic increase in notification rates in 0-4-year-olds and 5-9-year-olds from the 2004-2008 pre-epidemic period to the 2008-2009 epidemic year, compared with a moderate increase in testing, which indicates that there probably was a true increase in disease for these groups during this period. It is possible that a real increase in 0-4-year-olds and 5-9-year-olds early on prompted increased disease awareness among GPs, leading to widespread increases in testing across all ages. A positive feedback loop due to increased testing -leading to increased disease detection and awareness, leading to increased testing, and so on -may have been established. This interpretation is supported by the observation that although testing continued to increase from the epidemic year [2008] [2009] to the epidemic year 2009-2010, there was little change in notifications, suggesting an increase in testing during that period rather than an increase in disease. In the other age groups, an increase in testing appeared to be responsible for magnified pertussis notifications. A study of pertussis resurgence in Toronto, Canada, also described this phenomenon and concluded that, although there had been true increase in local disease activity, the apparent size of the increase had been magnified by an increase in the use of pertussis testing and improvements in test sensitivity. 4 In Australia, public funding for pathology laboratories to use PCR to test specimens for pertussis (and other pathogens) commenced under the Medicare Benefits Schedule (MBS) in November 2005. 17 This specific reimbursement for PCR testing (MBS item 69494) -a Medicare fee of $28.65 compared with $22.00 for culture (MBS item 69303) and $15.65 for serological testing (MBS item 69384) 17 may have been an incentive for laboratories across Australia to implement PCR testing more routinely. In addition, during the 2009 H1N1 influenza pandemic, public funding was allocated for the purchase of laboratory equipment (notably PCR suites), but much of the funding was not received by laboratories until after the demand for pandemic influenza testing had subsided. 18 New PCR capacity may have provided an increased opportunity for laboratories to conduct PCR testing for other pathogens, such as B. pertussis.
Several factors may have contributed to an increase in disease during the study period. Pertussis laboratory testing methods have been documented to vary between children and adults. While, historically, culture would have been preferred to serological tests for the very young, 19 children now are more likely to be tested using PCR, and adults are predominantly tested using serological tests. 10 The variation in testing and notification rates across age groups may be due to differences in susceptibility and immunity. 20 Pertussis vaccination does not provide lifelong immunity against infection, with protection waning between booster doses. 21 Waning immunity may partially explain differences in pertussis incidence between age groups, with older individuals having lower immunity due to longer periods since vaccination. 20 Furthermore, there is evidence to suggest that whole-cell pertussis vaccine formulations used in Australia and overseas before the late 1990s were more protective against B. pertussis infection than currently used acellular pertussis vaccines, 14, [22] [23] [24] resulting in immunity levels waning faster in some age cohorts due to changes in vaccination schedules. 25 In addition, a recent analysis of B. pertussis isolates collected in Australia between 2008 and 2010 indicates that there has been increasing circulation of vaccine-mismatched strains, hypothesised to be due to the selective pressure of vaccine-induced immunity. 26 While these or other factors may have led to a true increase in disease during the study period, our data suggest that increased testing, most likely due to expanding use of PCR during the study period, has almost certainly amplified the magnitude of notified pertussis activity in Australia. This increase in testing might have led to identification of illness that would have otherwise gone undetected among age groups in which pertussis circulates widely or age groups in which pertussis had previously been largely left as a clinical diagnosis.
Our findings have global implications, particularly for countries with high or expanding PCR availability. They highlight the critical importance of analysing changes in infectious diseases using a range of surveillance systems. By monitoring changes in laboratory testing and using surveillance datasets that do not rely on laboratory test results, it is possible to determine whether increases in notifications for diseases such as pertussis are due to a true increase in disease, an increase in testing, or a combination of both.
